= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Chaudhari

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 11:20 (Chair: Renee Ruhaak)

Combination of Stable Labelled Antibodies and LC-MS to Accurately Quantify Therapeutic Monoclonal Antibodies in the Clinical Laboratory

Ravindra Chaudhari (Presenter)
PROMISE Advanced Proteomics

Authors: Dorothée LEBERT1, Guillaume PICARD1, Ravindra CHAUDHARI1, Aurélien MILLET2, Jérôme GUITTON2, Jean-François JOURDIL3, Françoise STANKE3.
1 Promise Advanced Proteomics, F-38040, Grenoble, France 2 Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de pharmaco-toxicologie, F-69495, Pierre Bénite, France. 3 CHU Grenoble, Laboratoire de pharmaco-toxicologie, F-38000, Grenoble, France


We will present an innovative and generic approach involving the use of stable isotope labeled mAbs used as internal standards and LC-MS to allow accurate, sensitive and specific quantification, as required for therapeutic drug monitoring. Our approach was already tested and implemented with success in pharmacology laboratories on anti-TNF antibodies (Infliximab and Adalimumab) and was recently implemented for monitoring Cetuximab.

Financial Disclosure

GrantsyesPROMISE Advanced Proteomics
SalaryyesPROMISE Advanced Proteomics
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: